Why is the James Hardie share price surging higher today

We look at what's driving the recovery in the building materials company's shares on Wednesday.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • The James Hardie share price has recovered yesterday's losses and more this morning
  • The recovery comes amid a leading broker saying the company's shares are "too cheap to ignore"
  • James Hardie shares closed 3.5% lower on Tuesday after the company announced its latest results

The James Hardie Industries plc (ASX: JHX) share price more than rebounded from yesterday's sharp losses after a top broker upgraded its shares.

The ASX building materials supplier is "too cheap to ignore", according to Morgan Stanley. The broker upgraded its recommendation on James Hardie to "overweight" from "equal-weight" following the company's results announcement that triggered the sell-off.

A group of three builders wearing worker overalls and carrying hard hats in their hands jumps jubilantly atop a rooftop space on a commercial building.

Image source; Getty Images

When 36% profit growth isn't enough

The company posted a 36% increase in FY22 adjusted net profit to US$620.7 million which didn't impress the market. As a result, the James Hardie share price tumbled 3.5% on Tuesday although it regained all the loss, and then some, this morning when it surged as high as 6% to $39.79.

At the time of writing, the company's share price has settled at $39.00, 4% higher than yesterday's close.

It wasn't James Hardie's earnings or sales figures that scared investors. If anything, net profit was largely in line with consensus expectations.

Is too much bad news priced into the James Hardie share price?

Yesterday's negative reaction to the James Hardie share price likely stems from worries about the impact of rising interest rates on housing.

Morgan Stanley said:

JHX is a quality business with a true structural growth theme.

Current mortgage rate concerns are valid – but after material recent de-rating, we find housing market weakness more than priced in, particularly given JHX's skew towards R&R [repair and renovation] markets.

Building up to strong growth in FY23

Around 65% of the group's business is from R&R with the balance from new builds. The broker also reckons the company could steal market share to maintain its growth rate.

It also helps that James Hardie has a full backlog of orders that should keep it busy till FY23, if not beyond.

Further, management is sticking to its FY23 earnings guidance for net profit of US$740 million to US$820 million.

It also increased its revenue growth forecast for its North America Fibre Cement (NAFC) business to 18% to 22%. That's up from its original expectation of between 16% and 20%.

Morgan Stanley's 12-month price target on the James Hardie share price is $51 a share.

What other brokers are saying about the James Hardie share price

But the broker isn't the only one that is bullish on the shares. Citigroup and UBS have reiterated their buy call on James Hardie.

Citi acknowledges the risk of rising rates, particularly in the US. But it estimated that only around 2% to 3% market growth is factored into the company's North American sales guidance.

UBS also pointed out that its buy thesis on James Hardie is largely unchanged despite the macroeconomic risks.

The Citi and UBS 12-month price targets on the James Hardie share price are $44.30 and $57.70 respectively.

Motley Fool contributor Brendon Lau has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

A smiling woman holds a Facebook like sign above her head.
Broker Notes

Why these ASX shares are rated as buys in April

Let's see what makes them bullish on these names right now.

Read more »

Australian dollar notes in the pocket of a man's jeans, symbolising dividends.
Broker Notes

Are CBA shares still a good buy for passive income?

A leading analyst delivers his verdict on CBA’s passive income appeal.

Read more »

A financial expert or broker looks worried as he checks out a graph showing market volatility.
Broker Notes

Morgans names 2 ASX shares to buy and 1 to accumulate

What is the broker recommending investors do with these shares?

Read more »

A man in a business suit rides a graphic image of an arrow that is rebounding on a graph.
Broker Notes

2 ASX 200 shares to buy ahead of anticipated rally: expert

After a 9.1% drop between 27 February and 23 March, the ASX 200 reversed course last Tuesday.

Read more »

A group of people in a corporate setting do a collective high five.
Broker Notes

3 reasons to buy Ramsay Health Care shares today

A leading analyst expects Ramsay Health Care shares to keep outperforming in the months ahead.

Read more »

A woman presenting company news to investors looks back at the camera and smiles.
Broker Notes

Bell Potter says this ASX 200 stock can rise 38% and pay a 6% dividend yield

Major upside and a generous dividend yield could be on offer with this name.

Read more »

Middle age caucasian man smiling confident drinking coffee at home.
Broker Notes

Is this ASX defence stock the next DroneShield?

Bell Potter thinks this stock could be the next to rocket. Let's find out why.

Read more »

Happy, tablet or doctor in a laboratory with research results or positive feedback after medical data analysis. Smile, vaccine or healthcare worker reading or working on futuristic science innovation.
Broker Notes

This ASX healthcare stock could almost double in value according to Bell Potter

The broker believes this stock is making major breakthroughs.

Read more »